Dendritic Cell-Based Immunotherapy of Breast Cancer: Modulation by CpG DNA
Abstract
Breast cancer is the most common non-skin cancer in women, and the American Cancer Society estimates that there will be 203,500 new cases of invasive breast cancer and 40,000 deaths form metastatic breast cancer (MBC) in the U.S. in 2002. Thus, patients with MBC who fail conventional therapies are candidates for clinical trials using novel therapies, including immunotherapy. Dendritic cells (DC) are potent antigen-presenting cells that prime antitumor cytotoxic T lymphosytes against tumor-associated antigens and bacterial DNA oligodeoxynucleotides containing unmethylated CpC seouences (CpG DNA) further augment the immune priming functions of DCs. We hypothesize that CpC DNA-stimulated DCs will prime a more potent anti-tumor immune response than non-stimulated DCs. Tn year 2 of this proposal, our 2 specific aims are 1) to study the mechanism of antitumor immunity mediated by the vaccination of TS/A mammary tumor-bearing BALB/c mice with CpG DNA-stimulated DCs primed in vitro withnecrotic TS/A cells and 2) to determine optimal conditions for CpC DNA stimulation and tumor priming of human DCs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2003
- Accession Number
- ADA423383
Entities
People
- Joseph Baar
Organizations
- University of Pittsburgh